Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game [Seeking Alpha]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Seeking Alpha
Obesity drugs, particularly via Metsera, represent a potential $150B TAM, though market skepticism persists until Phase III data matures. PFE's forward multiple of 9.3x is well below sector medians, suggesting the market has largely priced in revenue challenges, leaving room for re-rating on positive execution. I'm maintaining my Buy rating on PFE, as the market appears to have not given enough respect for Pfizer's turnaround game yet. Looking for a helping hand in the market? Members of Ultimate Growth Investing get exclusive ideas and guidance to navigate any climate. Learn More » Alexandros Michailidis/iStock Editorial via Getty Images Whenever I think about the thesis for Pfizer Inc. ( PFE ), I can't help but ruminate over why the market has not shown much conviction despite PFE trading at valuations that are still undisputably More on my IG service A Growth Investing Service To Help You Outperform I'm a firm believer in growth, and tech plays as the core anchor o
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- ViiV Healthcare’s long-acting Cabenuva (cabotegravir + rilpivirine) for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges; results published in NEJMBusiness Wire
- Pfizer: The Rebound Looks Unsustainable [Seeking Alpha]Seeking Alpha
- ViiV Healthcare showcases long-acting HIV innovation and potential of ultra long-acting pipeline, including new data for first third-generation integrase inhibitor at CROI 2026Business Wire
- Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal CancerBusiness Wire
- Pfizer (NYSE:PFE) was downgraded by analysts at Daiwa America from a "strong-buy" rating to a "hold" rating.MarketBeat
PFE
Earnings
- 2/3/26 - Beat
PFE
Sec Filings
- 2/17/26 - Form 4
- 2/12/26 - Form 13F-HR
- 2/3/26 - Form 8-K
- PFE's page on the SEC website